UPC announces new public hearing for 10x Genomics
Hearing is latest in dispute between the biotech research firms | Multi-jurisdictional case concerns patents relating to the in-situ detection of analytes.
The Unified Patent Court (UPC) has announced a fresh public oral hearing in the dispute between NanoString Technologies and 10x Genomics, to take place in Luxembourg on Monday, December 18.
Both 10x and NanoString are biotechnology research companies specialising in single-cell spatial transcriptomics (SST), and have been at odds in multiple jurisdictions over patents relating to the in-situ detection of analytes.
10x alleges that Nanostring’s CosMx products for ribonucleic acid (RNA) detection infringe its European patents 2 794 928 B1, and 4 108 782 B1; and that Vizgen’s Merscope products infringe the ‘782 patent.
The panel of judges at the hearing will be Klaus Grabinski (presiding judge and judge rapporteur), Peter Blok, Françoise Barutel, Rainer Friedrich (TQJ), and Cornelis Schüller (TQJ).
The hearing, which concerns Appeal Rule 220.1 RoP, begins at 9am on December 18, with the proceeding in German and the oral hearing language in English.
The first two public hearings for this case were held at Munich local division in September, and were the first of their kind to be announced by the UPC.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
